BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 9042594)

  • 1. Magnitude of tolerance to fentanyl is independent of mu-opioid receptor density.
    Chan KW; Duttory A; Yoburn BC
    Eur J Pharmacol; 1997 Jan; 319(2-3):225-8. PubMed ID: 9042594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of the irreversible mu-opioid receptor antagonist clocinnamox on morphine potency, receptor binding and receptor mRNA.
    Chan K; Brodsky M; Davis T; Franklin S; Inturrisi CE; Yoburn BC
    Eur J Pharmacol; 1995 Dec; 287(2):135-43. PubMed ID: 8749027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clocinnamox dose-dependently antagonizes morphine-analgesia and [3H]DAMGO binding in rats.
    Paronis CA; Woods JH
    Eur J Pharmacol; 1997 Oct; 337(1):27-34. PubMed ID: 9389377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2.
    Pawar M; Kumar P; Sunkaraneni S; Sirohi S; Walker EA; Yoburn BC
    Eur J Pharmacol; 2007 Jun; 563(1-3):92-101. PubMed ID: 17349996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irreversible opioid antagonist effects of clocinnamox on opioid analgesia and mu receptor binding in mice.
    Burke TF; Woods JH; Lewis JW; Medzihradsky F
    J Pharmacol Exp Ther; 1994 Nov; 271(2):715-21. PubMed ID: 7965787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The analgesic efficacy of fentanyl: relationship to tolerance and mu-opioid receptor regulation.
    Sirohi S; Dighe SV; Walker EA; Yoburn BC
    Pharmacol Biochem Behav; 2008 Nov; 91(1):115-20. PubMed ID: 18640146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Supersensitivity to opioid analgesics following chronic opioid antagonist treatment: relationship to receptor selectivity.
    Yoburn BC; Shah S; Chan K; Duttaroy A; Davis T
    Pharmacol Biochem Behav; 1995; 51(2-3):535-9. PubMed ID: 7667382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of clocinnamox blockade of opioid receptors: evidence from in vitro and ex vivo binding and behavioral assays.
    Zernig G; Burke T; Lewis JW; Woods JH
    J Pharmacol Exp Ther; 1996 Oct; 279(1):23-31. PubMed ID: 8858971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mu-Opioid receptor downregulation contributes to opioid tolerance in vivo.
    Stafford K; Gomes AB; Shen J; Yoburn BC
    Pharmacol Biochem Behav; 2001; 69(1-2):233-7. PubMed ID: 11420091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydromorphone efficacy and treatment protocol impact on tolerance and mu-opioid receptor regulation.
    Kumar P; Sunkaraneni S; Sirohi S; Dighe SV; Walker EA; Yoburn BC
    Eur J Pharmacol; 2008 Nov; 597(1-3):39-45. PubMed ID: 18789923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioid receptor regulation in mice.
    Yoburn BC; Billings B; Duttaroy A
    J Pharmacol Exp Ther; 1993 Apr; 265(1):314-20. PubMed ID: 8386239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clocinnamox distinguishes opioid agonists according to relative efficacy in normal and morphine-treated rats trained to discriminate morphine.
    Walker EA; Young AM
    J Pharmacol Exp Ther; 2002 Jul; 302(1):101-10. PubMed ID: 12065706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of cAMP-dependent protein kinase (PKA) in opioid agonist-induced mu-opioid receptor downregulation and tolerance in mice.
    Shen J; Benedict Gomes A; Gallagher A; Stafford K; Yoburn BC
    Synapse; 2000 Dec; 38(3):322-7. PubMed ID: 11020235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delta opioid receptor enhancement of mu opioid receptor-induced antinociception in spinal cord.
    He L; Lee NM
    J Pharmacol Exp Ther; 1998 Jun; 285(3):1181-6. PubMed ID: 9618421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of irreversible antagonists to determine the relative efficacy of mu-opioids in a pigeon drug discrimination procedure: comparison of beta-funaltrexamine and clocinnamox.
    Barrett AC; Smith ES; Picker MJ
    J Pharmacol Exp Ther; 2003 Jun; 305(3):1061-70. PubMed ID: 12649297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [(35)S]GTPĪ³S binding and opioid tolerance and efficacy in mouse spinal cord.
    Madia PA; Navani DM; Yoburn BC
    Pharmacol Biochem Behav; 2012 Mar; 101(1):155-65. PubMed ID: 22108651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nitrocinnamoyl and chlorocinnamoyl derivatives of dihydrocodeinone: in vivo and in vitro characterization of mu-selective agonist and antagonist activity.
    McLaughlin JP; Hill KP; Jiang Q; Sebastian A; Archer S; Bidlack JM
    J Pharmacol Exp Ther; 1999 Apr; 289(1):304-11. PubMed ID: 10087018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of morphine tolerance and dependence by diazepam and its relation to mu-opioid receptors in the rat brain and spinal cord.
    Tejwani GA; Sheu MJ; Sribanditmongkol P; Satyapriya A
    Brain Res; 1998 Jun; 797(2):305-12. PubMed ID: 9666154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of naltrexone on the binding of [3H]D-Ala2, MePhe4, Gly-ol5-enkephalin to brain regions and spinal cord and pharmacological responses to morphine in the rat.
    Bhargava HN; Matwyshyn GA; Reddy PL; Veeranna
    Gen Pharmacol; 1993 Nov; 24(6):1351-7. PubMed ID: 8112506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo determination of mu opioid receptor turnover in rhesus monkeys after irreversible blockade with clocinnamox.
    Zernig G; Butelman ER; Lewis JW; Walker EA; Woods JH
    J Pharmacol Exp Ther; 1994 Apr; 269(1):57-65. PubMed ID: 8169852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.